CollPlant Biotechnologies Ltd. Sponsored ADR (NASDAQ:CLGN – Get Free Report)’s share price was down 3.8% during mid-day trading on Thursday . The stock traded as low as $1.47 and last traded at $1.50. Approximately 66,522 shares changed hands during trading, an increase of 102% from the average daily volume of 32,879 shares. The stock had previously closed at $1.56.
Wall Street Analyst Weigh In
Separately, D. Boral Capital lowered their price target on CollPlant Biotechnologies from $14.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, May 28th.
View Our Latest Stock Analysis on CollPlant Biotechnologies
CollPlant Biotechnologies Stock Down 3.8%
CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) last released its quarterly earnings data on Wednesday, June 4th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.24. The business had revenue of $2.06 million during the quarter, compared to analysts’ expectations of $9.76 million. CollPlant Biotechnologies had a negative net margin of 560.92% and a negative return on equity of 87.33%. Equities research analysts expect that CollPlant Biotechnologies Ltd. Sponsored ADR will post -1.44 earnings per share for the current year.
Institutional Investors Weigh In On CollPlant Biotechnologies
Large investors have recently modified their holdings of the business. Wells Fargo & Company MN lifted its holdings in shares of CollPlant Biotechnologies by 110.1% during the 4th quarter. Wells Fargo & Company MN now owns 8,405 shares of the company’s stock valued at $30,000 after purchasing an additional 4,405 shares in the last quarter. Renaissance Technologies LLC bought a new stake in CollPlant Biotechnologies during the 4th quarter worth approximately $38,000. Finally, AMH Equity Ltd raised its holdings in CollPlant Biotechnologies by 17.4% during the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after buying an additional 17,295 shares during the period. 21.69% of the stock is currently owned by institutional investors.
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.
Further Reading
- Five stocks we like better than CollPlant Biotechnologies
- Market Cap Calculator: How to Calculate Market Cap
- Robinhood Director Sells Millions, But HOOD Stock Eyes Gains
- How to Calculate Options Profits
- Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill
- How to Use the MarketBeat Excel Dividend Calculator
- Super Micro Computer Stock’s Rally Backed by Strong Financials
Receive News & Ratings for CollPlant Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CollPlant Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.